Dataset from A Prospective, Open-Label, Multi-Center, Dose-Optimization Study Evaluating the Efficacy, Safety and Tolerability of Vyvanse (Lisdexamfetamine Dimesylate) 20-70mg in Children Aged 6-12 Diagnosed With ADHD
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://doi.org/10.25934/PR00007901
下载链接
链接失效反馈官方服务：
资源简介：
Assess the efficacy & tolerability of Vyvanse when children aged 6-12 years diagnosed with
ADHD are dosed to optimal effect.
创建时间：
2024-11-26
